Literature DB >> 3110477

Modulation of cell proliferation by human recombinant interleukin-1 and immune interferon.

S C Tsai, E V Gaffney.   

Abstract

The growth-modulating effects of recombinant alpha- and beta-forms of human interleukin-1 (IL-1) and interferon-gamma (IFN-gamma) were examined with several human cell lines. Exposure to combinations of IL-1 and IFN-gamma resulted in three categories of cell response. The first was cell lines in which IL-1 stimulated growth and offset the growth inhibitory effects of IFN-gamma. These lines included the lung carcinoma CALU-1 and the colon carcinoma SW-48. The second was some of the cell lines that were refractory to IL-1 and that were inhibited by IFN-gamma alone. These included the cervical carcinoma HeLa, the transformed milk line HBL-100, and the myelogenous leukemia K562. The third group consisted of cells in which growth inhibition by IL-1 and IFN-gamma was additive. These included the mammary carcinomas MCF-7 and MDA-MB-415. The exception to this latter group was ME-180 in which significant additive inhibitory effects could not be demonstrated. IL-1 alone primarily induced a cytostatic effect in growth-inhibited cell lines. The cytolytic effect induced by IFN-gamma was increased in the presence of IL-1. The data support the conclusion that the effects on growth of IL-1 and IFN-gamma are mediated by different mechanisms.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3110477

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  2 in total

1.  Recombinant interleukin-1 alpha inhibits the growth of rat mesangial cells in culture.

Authors:  M Ikeda; U Ikeda; T Oohara; K Takeda; S Kano
Journal:  Clin Exp Immunol       Date:  1991-01       Impact factor: 4.330

2.  Interleukin 1 modulates growth of human renal carcinoma cells in vitro.

Authors:  I Koch; H Depenbrock; S Danhauser-Riedl; J W Rastetter; A R Hanauske
Journal:  Br J Cancer       Date:  1995-04       Impact factor: 7.640

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.